Retrieve available abstracts of 33 articles: HTML format
Single Articles
May 2025
XIANG G, Zhu P, Zhang L, Yu S, et al Effective leukemia-to-granulocyte induction by a cocktail of RUNX1, SPI1 and
CEBPE.
Cancer Lett. 2025;626:217820. PubMed
HU LJ, Li CY, Xing T, Wang Y, et al N-acetyl-L-cysteine promoted hematopoietic recovery in patients with acute
myeloid leukemia after complete remission--A pilot study.
Cancer Lett. 2025 May 20:217812. doi: 10.1016/j.canlet.2025.217812. PubMedAbstract available
April 2025
MA XH, Gao MG, Cheng RQ, Qin YZ, et al The expression level of EVI1 and clinical features help to distinguish prognostic
heterogeneity in the AML entity with EVI1 overexpression.
Cancer Lett. 2025;615:217547. PubMedAbstract available
LIU Y, Tu Y, Yan Z, Xiao J, et al CAR T-Cell Therapy in Chronic Myeloid Leukemia Patients with Lymphoid Blast
Crisis: A Multicenter Clinical Analysis.
Cancer Lett. 2025 Apr 1:217688. doi: 10.1016/j.canlet.2025.217688. PubMed
March 2025
WANG Y, Liu W, Gu Z, Chang Y, et al Allogeneic versus autologous hematopoietic stem cell transplantation for adult
T-lymphoblastic lymphoma: a real-world multicenter analysis in China.
Cancer Lett. 2025 Mar 21:217664. doi: 10.1016/j.canlet.2025.217664. PubMedAbstract available
February 2025
CHEN DW, Schrey JM, Wafula EK, Fan JM, et al Leukemia confers a durable imprint on healthy hematopoietic stem and progenitor
cells.
Cancer Lett. 2025;616:217590. PubMedAbstract available
LIU C, Liu G, Zhou F, Chen L, et al EBF1-induced CSRP2 boosts the progression of B-cell acute lymphocytic leukemia by
inhibiting ferroptosis.
Cancer Lett. 2025;614:217556. PubMedAbstract available
January 2025
WEISS S, Zdarsky B, Witalisz-Siepracka A, Edtmayer S, et al Atovaquone and selinexor as a novel combination treatment option in acute myeloid
leukemia.
Cancer Lett. 2025;613:217501. PubMedAbstract available
LI M, Li Y, Qu Q, Wang C, et al Clinical features and prognostic nomogram for therapy-related acute myeloid
leukemia after allogeneic hematopoietic stem cell transplantation.
Cancer Lett. 2025 Jan 11:217460. doi: 10.1016/j.canlet.2025.217460. PubMedAbstract available
PEI HZ, Guo Y, Zhao Y, Zhang D, et al FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive
interactions in acute myeloid leukemia.
Cancer Lett. 2025;611:217446. PubMedAbstract available
December 2024
WANG J, Ma W, Huang J, Qiu G, et al Corrigendum to "HIF-2alpha 1 inhibition disrupts leukemia stem cell metabolism and
impairs vascular microenvironment to enhance chronic myeloid leukemia treatment"
[Cancer lett. 597 (2024) 217060].
Cancer Lett. 2024 Dec 31:217435. doi: 10.1016/j.canlet.2024.217435. PubMed
JIN P, Shen J, Zhao M, Yu J, et al Driver mutation landscape of acute myeloid leukemia provides insights for
neoantigen-based immunotherapy.
Cancer Lett. 2024 Dec 24:217427. doi: 10.1016/j.canlet.2024.217427. PubMedAbstract available
VAN TRIMPONT M, Schalk AM, Hofkens K, Peeters E, et al A human-like glutaminase-free asparaginase is highly efficacious in ASNS(low)
leukemia and solid cancer mouse xenograft models.
Cancer Lett. 2024 Dec 19:217404. doi: 10.1016/j.canlet.2024.217404. PubMedAbstract available
November 2024
WANG Y, Chang YJ, Chen J, Han M, et al Consensus on the monitoring, treatment, and prevention of leukaemia relapse after
allogeneic haematopoietic stem cell transplantation in China: 2024 update.
Cancer Lett. 2024;605:217264. PubMedAbstract available
HLOZKOVA K, Vasylkivska M, Boufersaoui A, Marzullo B, et al Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase.
Cancer Lett. 2024;605:217242. PubMedAbstract available
October 2024
WANG ZK, Zhang ZW, Lyu ZS, Xing T, et al Inhibition of TGF-beta signaling in bone marrow endothelial cells promotes
hematopoietic recovery in acute myeloid leukemia patients.
Cancer Lett. 2024;605:217290. PubMedAbstract available
August 2024
WANG YQ, Ren Y, Gale RP, Niu LT, et al Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute
myeloid leukemia stem cells.
Cancer Lett. 2024 Aug 5:217158. doi: 10.1016/j.canlet.2024.217158. PubMedAbstract available
July 2024
LIU T, Gu L, Mui A, Wu Z, et al An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute
lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues.
Cancer Lett. 2024 Jul 23:217126. doi: 10.1016/j.canlet.2024.217126. PubMedAbstract available
LIU Y, Zheng L, Li Y, Ma L, et al Neratinib impairs function of m6A recognition on AML1-ETO pre-mRNA and induces
differentiation of t (8;21) AML cells by targeting HNRNPA3.
Cancer Lett. 2024;594:216980. PubMedAbstract available
YAN N, Wang ZL, Wang XJ, Gale RP, et al Measurable residual disease testing by next generation sequencing is more
accurate compared with multiparameter flow cytometry in adults with B-cell acute
lymphoblastic leukemia.
Cancer Lett. 2024;598:217104. PubMedAbstract available
YAO M, Jiang X, Xiao F, Lv X, et al Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine
resistance.
Cancer Lett. 2024;593:216949. PubMedAbstract available
June 2024
WANG J, Ma W, Huang J, Qiu G, et al HIF-2alpha Inhibition Disrupts Leukemia Stem Cell Metabolism and Impairs Vascular
Microenvironment to Enhance Chronic Myeloid Leukemia Treatment.
Cancer Lett. 2024 Jun 14:217060. doi: 10.1016/j.canlet.2024.217060. PubMedAbstract available
YUAN J, Zhang J, Zhao B, Liu F, et al Single-cell transcriptomic analysis of the immune microenvironment in pediatric
acute leukemia.
Cancer Lett. 2024 Jun 4:217018. doi: 10.1016/j.canlet.2024.217018. PubMedAbstract available
May 2024
XU M, Li S The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia
treatment.
Cancer Lett. 2024;593:216969. PubMedAbstract available
WANG D, He J, Liu S, Zhang H, et al Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute
myeloid leukemia.
Cancer Lett. 2024 May 17:216970. doi: 10.1016/j.canlet.2024.216970. PubMedAbstract available
TAN Y, Xin L, Wang Q, Xu R, et al FLT3-Selective PROTAC: Enhanced Safety and Increased Synergy with Venetoclax in
FLT3-ITD Mutated Acute Myeloid Leukemia.
Cancer Lett. 2024 May 3:216933. doi: 10.1016/j.canlet.2024.216933. PubMedAbstract available
April 2024
ZHAO Y, Chen W, Yu J, Pei S, et al TP53 in MDS and AML: Biological and clinical advances.
Cancer Lett. 2024;588:216767. PubMedAbstract available
SUN H, Xie Y, Wu X, Hu W, et al circRNAs as prognostic markers in pediatric acute myeloid leukemia.
Cancer Lett. 2024;591:216880. PubMedAbstract available
March 2024
HE Y, Jiang S, Cui Y, Liang J, et al Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of
myeloma and leukemia via pyroptosis.
Cancer Lett. 2024 Mar 8:216797. doi: 10.1016/j.canlet.2024.216797. PubMedAbstract available
February 2024
CHENG C, Liang S, Yue K, Wu N, et al STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity
of Vdelta2(+) T cells in acute myeloid leukemia.
Cancer Lett. 2024 Feb 13:216730. doi: 10.1016/j.canlet.2024.216730. PubMedAbstract available
January 2024
YANG F, Cui X, Wang H, Zhang D, et al Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia
by upregulation of FOS.
Cancer Lett. 2024 Jan 17:216652. doi: 10.1016/j.canlet.2024.216652. PubMedAbstract available
December 2023
JUNG YY, Ahn KS, Shen M Unveiling autophagy complexity in leukemia: The molecular landscape and possible
interactions with apoptosis and ferroptosis.
Cancer Lett. 2023 Dec 1:216518. doi: 10.1016/j.canlet.2023.216518. PubMedAbstract available
September 2023
WEN J, Chen Y, Liao C, Ma X, et al Engineered mesenchymal stem cell exosomes loaded with miR-34c-5p selectively
promote eradication of acute myeloid leukemia stem cells.
Cancer Lett. 2023 Sep 26:216407. doi: 10.1016/j.canlet.2023.216407. PubMedAbstract available